Astellas Pharma Inc (ALPMF)
OTHER OTC:ALPMF
Holding ALPMF?
Track your performance easily

Astellas Pharma (ALPMF) Financial Statements

44 Followers

Astellas Pharma Financial Overview

Astellas Pharma's market cap is currently ―. The company's EPS TTM is $0.198; its P/E ratio is 59.07; and it has a dividend yield of 4.15%. Astellas Pharma is scheduled to report earnings on January 30, 2025, and the estimated EPS forecast is $0.12. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue¥ 402.18B-¥ 381.79B¥ 303.87B¥ 340.63B
Gross Profit¥ 327.76B-¥ 292.92B¥ 244.96B¥ 271.27B
EBIT¥ 62.56B-¥ 34.08B¥ -9.84B¥ 79.62B
EBITDA¥ 85.56B-¥ 70.95B¥ 11.24B¥ 101.14B
Net Income Common Stockholders¥ 48.41B-¥ 24.81B¥ -8.41B¥ 60.88B
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments¥ 413.30B¥ 0.00¥ 336.76B¥ 337.28B¥ 368.09B
Total Assets¥ 2.51T-¥ 2.48T¥ 2.33T¥ 2.36T
Total Debt¥ 0.00¥ 0.00¥ 0.00¥ 0.00¥ 0.00
Net Debt¥ -413.30B¥ 0.00¥ -336.76B¥ -337.28B¥ -368.09B
Total Liabilities--¥ 942.79B¥ 872.09B¥ 889.95B
Stockholders Equity¥ 1.57T¥ 0.00¥ 1.54T¥ 1.46T¥ 1.47T
Cash Flow-
Free Cash Flow¥ 51.58B-¥ 30.57B¥ 31.31B¥ 58.17B
Operating Cash Flow¥ 72.32B-¥ 48.83B¥ 48.59B¥ 69.47B
Investing Cash Flow¥ -27.12B-¥ -19.14B¥ -14.83B¥ 8.16B
Financing Cash Flow¥ -9.69B-¥ -46.60B¥ -75.03B¥ -51.33B
Currency in JPY

Astellas Pharma Earnings and Revenue History

Astellas Pharma Debt to Assets

Astellas Pharma Cash Flow

Astellas Pharma Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis